AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) A polymer composition comprising:

 a co-polymer comprising at least a first and a second monomer, wherein the first

 monomer comprises glycolic acid (GA) as a co-polymer with at least one other, and wherein
 the second monomer comprises a bioresorbable monomer, or
 - a functional derivative of said co-polymer[[,]];

wherein the polymer composition has having a tensile strength of at least 1100MPa; and

wherein the polymer composition has a tensile modulus of at least 20 GPa.

- 2. (Currently Amended) The polymer composition as claimed in of claim 1, wherein the polymer composition comprises a blend of the co-polymer and at least one other polymer in which there are two bioresorbable monomers.
- 3. (Currently Amended) The polymer composition as elaimed in of claim 1, in which the at least one other bioresorbable wherein the second monomer is comprises polylactic acid (PLA).
- 4. (Currently Amended) The polymer composition as claimed in of claim 3 1, in which the at least one other bioresorbable monomer is wherein the second monomer comprises poly L-lactic acid (PLA).
- 5. (Currently Amended) The polymer composition as claimed in of claim 1, in which the GA wherein the polymer composition is comprises at least 70% glycolic acid.

- 6. (Currently Amended) The polymer composition as claimed in of claim 5, in, which the GA wherein the polymer composition is comprises at least 75, 80, 85, 90 or 95% glycolic acid.
- 7. (Currently Amended) The polymer composition as elaimed in of claim 6 [[4]], in which wherein the polymer composition is around comprises about 95% glycolic acid.
- 8. (Currently Amended) The polymer composition as elaimed in of claim 6 [[4]], in which wherein the polymer composition is around comprises about 98% glycolic acid.
- 9. (Cancelled)
- 10. (Cancelled)
- 11. (Currently Amended) The polymer composition as elaimed in of claim 1, in which wherein the polymer composition has fibres have a tensile modulus of at least 21GPa.
- 12. (Currently Amended) The polymer composition as elaimed of claim 4 11, in which wherein the polymer composition has fibres have a tensile modulus of at least 22GPa 220GPa.
- 13. (Currently Amended) A process for the manufacture of a <u>the</u> polymer composition as claimed in <u>of</u> claim 1, which includes the steps of <u>comprising</u>:
- a) forming the <u>a</u> polymer composition <u>into fibers</u>, wherein the <u>polymer</u> composition comprises comprising

a co-polymer comprising a first and a second monomer, wherein the first monomer comprises glycolic acid, and wherein the second monomer comprises a as a copolymer with at least one other bioresorbable monomer, or

- a functional derivative of the co-polymer thereof, into fibre;
- b) quenching the fibers fibres; and

- c) thereafter drawing a localized region of the fibers by subjecting the quenched fibers fibres to a tension under conditions whereby a defined region of the tensioned fibres is drawn.
- 14. (Currently Amended) The process according to of claim 13, in which wherein the fibre forming the polymer composition into fibers comprises method is melt extruding extrusion or solution spinning the polymer composition.
- 15. (Currently Amended) The process according to of claim 13, in which wherein drawing a defined region of the fibers further comprises the quenched, tensioned fibres are subjected to zone-heating the fibers.
- 16. (Currently Amended) The process according to of claim 13, wherein drawing a defined region of the fibers comprises in which the quenched, tensioned fibres are subjected to at least two separate drawing steps, each drawing step performed under identical or different conditions.¹
- 17. (Currently Amended) An artefact article comprising a at least one polymer composition, wherein the at least one polymer composition comprises the polymer composition of or the functional derivative thereof according to claim 1.
- 18. (Currently Amended) The <u>article</u> artefact of claim 17, wherein the at least one polymer composition further comprises comprising at least two a second polymer composition components.
- 19. (Currently Amended) The artefact article of claim 18 17, wherein the article comprises comprising 10% to 80% by volume of the polymer composition or the functional derivative.

Page 6 of 22

- 20. (Currently Amended) The artefact article of claim 18 17, in which at least one of the wherein the second polymer composition components is comprises at least one bioresorbable polymer.
- 21. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 20, <u>in which</u> <u>wherein</u> the bioresorbable polymer comprises a poly-hydroxy acid, a poly-lactic acid, a poly-caprolactone, a poly-acetal or a poly-anhydride.
- 22. (Currently Amended) The artefact article of claim 47 18, wherein the second polymer composition comprises comprising at least one non-bioresorbable polymer component.
- 23. (Currently Amended) The artefact article of claim 22, wherein in-which the at least one non-bioresorbable polymer component comprises poly-propylene, poly-ethylene, poly-methyl methacrylate or epoxy expoxy resin.
- 24. (Currently Amended) The artefact article of claim 17, further containing comprising at least one non-polymeric component.
- 25. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 24, <u>in which</u> <u>wherein</u> the <u>at</u> <u>least one</u> non-polymeric component comprises a ceramic, hydroxyapatite or tricalcium phosphate.
- 26. (Currently Amended) The artefact article of claim 24 25, in which wherein the at least one non-polymeric component comprises a bioactive component factor.
- 27. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 26, <u>in which wherein</u> the bioactive component comprises a natural or engineered protein, a ribonucleic acid, a deoxyribonucleic acid, a growth factor, a cytokine, an angiogenic factor or an antibody.

- 28. (Currently Amended) The <u>article</u> artefact according to <u>of</u> claim 17, in which wherein the <u>artefact</u> article comprises is in the form of a medical device.
- 29. (Currently Amended) The <u>artefact article</u> of claim 28, <u>in which wherein</u> the <u>medical</u> device <u>comprises</u> is a suture, a scaffold for tissue engineering or implantation, an orthopaedics implant, a complex shaped device or a bone fixation device.
- 30. (Currently Amended) A process to manufacture of the artefact for manufacturing an article comprising the polymer composition of claim 1, the process comprising according to claim 17, comprising the steps of:
- a) placing appropriate lengths of the strengthened glycolic acid polymer composition comprising glycolic acid (GA) as the co-polymer with the at least one other bioresorbable monomer, or the functional derivative of said co-polymer, having the tensile strength of at least 1100MPa, into a mold moulds;
- b) adding to the polymer composition and mixing any other components a component selected from the group consisting of polymers, bioresorbable polymers, non-polymeric components, and combinations thereof to the polymer composition; and
 - c) compression moulding molding to the desired shape.
- 31. (Currently Amended) <u>A The process to manufacture of the artefact according to claim 17, comprising the steps of for manufacturing an article comprising the polymer composition of claim 1, the process comprising:</u>
- a) combining the forming a polymeric component in the presence of strengthened glycolic acid polymer composition of claim 1 with at least one monomer or other precursor comprising glycolic acid (GA) as the co-polymer with the at least one other bioresorbable monomer, or the functional derivative of said co-polymer, having the tensile strength of at least 1100MPa; and[[;]]
- b) in situ curing of the <u>at least one monomer</u> monomers or other precursors precursor in situ to form said polymeric component and artefact.

32. (Currently Amended) The process for the manufacture of claim 30 the artefact according to claim 17, which includes the step of:

compression moulding other polymeric, non-polymeric or blend of polymeric and non-polymeric components in the presence of said fibers, wherein adding a component selected from the group consisting of polymers, bioresorbable polymers, non-polymeric components, and combinations thereof to the polymer composition is carried out prior to placing the polymer composition into the mold.

- 33. (Canceled)
- 34. (Canceled)
- 35. (Currently Amended) The process of claim 34 31, in which wherein curing the monomer or other precursor in situ used does not comprise liberating liberate a by-product on polymerization polymerisation.
- 36. (Currently Amended) The process of claim 34 31, in which wherein curing the monomer or other precursor in situ comprises at least one of the monomers is a ring opening monomer that opens to reaction that forms form a poly hydroxyl acid.
- 37. (Currently Amended) The process of claim 36, in which wherein combining the polymer composition with at least one monomer or precursor comprises combining the polymer composition with at least one monomer comprising is a lactide, a glycolide, a caprolactone, a carbonate or mixtures thereof.
- 38. (Currently Amended) An artefact article comprising at least one polymer composition, wherein the at least one polymer composition comprises a polymer composition, or the functional derivative thereof produced by the process according to of claim 13.

Page 9 of 22

- 39. (Previously Presented) The artefact article of claim 38 wherein the at least one polymer composition further comprises comprising at least two a second polymer composition components.
- 40. (Currently Amended) The article of claim 39 38, wherein the article comprises comprising 10% to 80% by volume of the polymer composition or the functional derivative thereof.
- 41. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 38, <u>in which</u> <u>wherein</u> at least one of the polymer <u>composition</u> or the second <u>polymer composition</u> <u>components</u> is <u>a</u> bioresorbable <u>polymer</u>.
- 42. (Currently Amended) The artefact article of claim 41, in which wherein the bioresorbable polymer comprises a poly-hydroxy acid, a poly-lactic acid, a poly-caprolactone, a poly-acetal or a poly-anhydride.
- 43. (Currently Amended) The artefact article of claim 38, further comprising at least one non-bioresorbable polymer component.
- 44. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 43, <u>in which</u> <u>wherein</u> the <u>at least one</u> non-bioresorbable polymer <u>component</u> comprises poly-propylene, poly-ethylene, poly-methyl methacrylate or expoxy resin.
- 45. (Currently Amended) The artefact article of claim 38 further comprising eontaining at least one non-polymeric component.
- 46. (Currently Amended) The <u>artefact</u> <u>article</u> of claim 45, <u>in which</u> <u>wherein</u> the <u>at least one</u> non-polymeric component comprises a ceramic, hydroxyapatite or tricalcium phosphate.

- 47. (Currently Amended) The <u>artefact</u> <u>article</u> of claim <u>45</u> 46, <u>in which</u> <u>wherein</u> the at least one non-polymeric component comprises a bioactive component factor.
- 48. (Currently Amended) The artefact article of claim 47, in which wherein the bioactive component comprises a natural or engineered protein, a ribonucleic acid, a deoxyribonucleic acid, a growth factor, a cytokine, an angiogenic factor or an antibody.
- 49. (Currently Amended) The artefact article of according to claim 38, in which wherein the artefact article comprises is in the form of a medical device.
- 50. (Currently Amended) The <u>artefact article</u> of claim 49, <u>in which wherein</u> the <u>medical</u> device <u>comprises</u> is a suture, a scaffold for tissue engineering or implantation, an orthopaedics implant, a complex shaped device or a bone fixation device.
- 51. (Currently Amended) A process to <u>for the</u> manufacture of the artefact according to <u>article of claim 38</u>, <u>further the process comprising the steps of:</u>
 - a) placing appropriate lengths of the strengthened glycolic acid polymer composition or functional derivative thereof comprising glycolic acid (GA) as the co-polymer with the at least one other bioresorbable monomer, or the functional derivative of said co-polymer, having the tensile strength of at least 1100MPa, into a mold moulds;
 - b) adding to the polymer composition a component selected from the group consisting of polymers, bioresorbable polymers, non-polymeric components, and combinations thereof and mixing any other components; and
 - c) compression moulding molding to the desired shape.
- 52. (Currently Amended) The A process for the to manufacture of the article of artefact according to claim 38, further the process comprising the steps of:
 - a) forming a polymeric component in the presence of combining the strengthened glycolic acid polymer composition or functional derivative thereof with at

Amendment and Response to Office Action Serial No. 10/565,029 Page 11 of 22

> least one monomer or other precursor comprising glycolic acid (GA) as the copolymer with the at least one other bioresorbable monomer, or the functional derivative of said co-polymer, having the tensile strength of at least 1100MPa, : and[[;]]

- b) in situ curing of the at least one monomer monomers or other precursor in situ precursors to form said polymeric component and artefact.
- 53. (Currently Amended) The process of for the manufacture of the artefact according to claim 51 38, which further includes the step of:

 compression moulding molding other polymeric, non-polymeric or blend of polymeric and non-polymeric components in the presence of said fibres wherein adding a component selected from the group consisting of polymers, bioresorbable polymers, non-polymeric components, and combinations thereof to the polymer composition is carried out prior to placing the polymer composition into the mold.
- 54. (Cancelled)
- 55. (Cancelled)
- 56. (Currently Amended) The process of claim <u>52</u> <u>55</u>, in which wherein curing the monomer <u>or other precursor in situ</u> used does not <u>comprise liberating liberate</u> a by-product on <u>polymerization</u> polymerisation.
- 57. (Currently Amended) The process of claim <u>52</u> <u>55</u>, in which wherein curing the monomer or other precursor in situ comprises at least one of the monomers is a ring opening monomer that opens to reaction that forms form a poly hydroxyl acid.
- 58. (Currently Amended) The process of claim <u>52</u> 57, in which wherein combining the polymer composition with at least one monomer or precursor comprises combining the

Amendment and Response to Office Action Serial No. 10/565,029 Page 12 of 22

<u>polymer composition with at least one monomer comprising is a lactide, a glycolide, a caprolactone, a carbonate or mixtures thereof.</u>